TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with UKONIQ^® as a Treatment for Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

TG Therapeutics, Inc. announced that the FDA has accepted the Biologics License Application for Ublituximab, the company’s investigational glycoengineered anti-CD20 monoclonal antibody, in combination with UKONIQ®, their inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.